Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer

Table 3 Prognostic factors for survival in univariate and multivariate analyses

Observation	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Model 1a
Gender
Male vs Female	0.932	0.984	0.684-1.417	0.991	0.998	0.685-1.454
Age/yr
≤50 vs >50	< 0.001	0.288	0.189-0.438	0.025	0.508	0.213-0.995
Location in the colon
Left vs Right	0.730	1.086	0.678-1.740	0.440	1.211	0.745-1.967
Location of tumor
Rectum vs Colon	0.232	1.311	0.840-2.047	0.017	1.795	1.111-2.902
Differentiation
Poor vs Well-moderate	0.002	0.426	0.472-0.734	0.923	0.972	0.542-1.741
Tumor stage
II vs III	0.034	0.651	0.437-0.968	0.041	0.601	0.321-0.932
Tumor size
<4 vs ≥4 cm	0.646	0.921	0.647-1.311	0.421	0.861	0.598-1.240
Lymphocytic infiltration
Positive vs Negative	< 0.001	2.282	1.092-5.756	0.022	3.665	1.207-7.128
Mucin
Positive vs Negative	0.001	2.361	1.647-3.383	< 0.001	2.512	1.714-4.682
Circumscribed margin
Positive vs Negative	< 0.001	3.908	2.654-5.755	0.011	2.474	1.433-4.270
MLH1/ MSH2
Positive vs Negative	< 0.001	3.799	2.205-6.546	< 0.001	4.064	2.241-7.369
Model 2b
Gender
Male vs Female	0.761	0.896	0.441-1.821	0.207	0.622	0.298-1.300
Age/yr
≤50 vs >50	< 0.001	0.150	0.075-0.302	< 0.001	0.131	0.063-0.271
MLH1/ MSH2
Positive vs Negative	0.014	4.833	1.382-16.899	0.011	5.583	1.478-21.092
Therapeutic regimen
Operation vs Operation + Chemotherapy	0.176	0.821	0.520-1.233	0.063	0.901	0.899-2.312
Model 3c
Gender
Male vs Female	0.964	0.990	0.647-1.517	0.748	0.932	0.607-1.432
Age/yr
≤50 vs >50	0.002	0.424	0.247-0.728	0.004	0.446	0.258-0.769
MLH1/ MSH2
Positive vs Negative	0.041	1.625	1.042-2.803	0.023	2.289	1.270-4.125
Therapeutic regimen
Operation vs Operation + Chemotherapy	0.028	2.891	1.209-6.372	< 0.001	4.002	1.929-9.425

^aAll 681 patients;

^b395 Patients with stage II CRC;

^c286 Patients with stage III CRC. HR: hazard ratio; CI: confidence interval; CRC: Colorectal cancer; MLH1: MutL homolog 1; MSH2: MutS homolog 2.